Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals, Inc. (https://www.regeneron.com/) is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

• Regeneron quarterly profit drops as COVID antibody sales hit (US.REGN) - 04 mai 2022
• Actiunile biotehnologice sunt pe sfarsite? Moderna (US.MRNA), BioNTech (US.BNTX), Regeneron Pharmaceuticals (US.REGN) - 17 februarie 2022
• Regeneron Pharmaceuticals Inc.